1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
DOC Biomaterials, Devices & Clinical Technologies Program is sponsored by National Institute of Dental and Craniofacial Research (NIDCR) / NIH. This program catalyzes end-to-end discovery, design, technology development, and translation of innovative materials, devices, and integrated systems intended to restore, preserve, manage, and optimize dental, oral, and craniofacial (DOC) health.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
DOC Biomaterials, Devices & Clinical Technologies Program | NIDCR DOC Biomaterials, Devices & Clinical Technologies Program The DOC Biomaterials, Devices & Clinical Technologies Program catalyzes end-to-end discovery, design, technology development, and translation of innovative materials, devices, and integrated systems intended to restore, preserve, manage, and optimize dental, oral, and craniofacial (DOC) health.
The program supports smart and high-performance biomaterials, imaging platforms, implantable devices, and diagnostic/therapeutic tools designed for the complex microenvironmental conditions (e.g., mechanical, chemical, and microbial) imposed by the oral cavity and unique DOC functions.
Emphasizing interdisciplinary collaboration and technical excellence, the program spans materials science, bioengineering, digital dentistry, imaging, and biosensing. SBIR/STTR-supported product development and regulatory science integration are encouraged to accelerate clinical adoption, patient-centered innovation, and technology commercialization.
Specific topics of interest include, but are not limited to: Functional and smart biomaterials Advanced restorative systems and preventive technologies Platforms for regenerative and multi-tissue repair Implantable devices and osseointegrative technologies Intraoral biosensing and digital diagnostics Digital dentistry and advanced manufacturing Digital twins and predictive modeling platforms Intelligent systems, robotics, and automation Novel and multimodal imaging and performance characterization Translational acceleration and data-driven design Resilience, accessibility, and user-centric innovation Previously Funded Grants (NIH RePORTER) DOC Biomaterials, Devices & Clinical Technologies Program
According to the current listing, eligibility includes: Emphasizes interdisciplinary collaboration and technical excellence. Supports research at academic institutions. Confirm the full requirements in the official notice before applying.
DOC Biomaterials, Devices & Clinical Technologies Program is funded by National Institute of Dental and Craniofacial Research (NIDCR) / NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article